 |
| |
| Feb-20-20 | Reiterated |
Needham |
Buy |
$50 → $48 |
|
| Jan-16-19 | Reiterated |
Needham |
Buy |
$66 → $64 |
|
| Apr-05-18 | Initiated |
Evercore ISI |
Outperform |
$56 |
|
| Mar-19-18 | Reiterated |
Mizuho |
Buy |
$28 → $35 |
|
| Mar-01-18 | Reiterated |
Needham |
Buy |
$28 → $30 |
|
| Jan-03-18 | Initiated |
Leerink Partners |
Outperform |
$22 |
|
| Sep-27-17 | Initiated |
Northland Capital |
Outperform |
$40 |
|
| Feb-27-17 | Initiated |
Needham |
Buy |
$28 |
|
| Oct-26-16 | Initiated |
Aegis Capital |
Buy |
|
|
| Sep-06-16 | Resumed |
Lake Street |
Buy |
$45 |
|
| May-03-16 | Initiated |
Cantor Fitzgerald |
Buy |
|
|
| Dec-10-15 | Initiated |
Lake Street |
Buy |
$45 |
|
| Sep-23-15 | Reiterated |
Leerink Partners |
Outperform |
$38 → $57 |
|
| Sep-02-15 | Initiated |
BofA/Merrill |
Buy |
$46 |
|
| Aug-03-15 | Reiterated |
Brean Capital |
Buy |
$40 → $45 |
|
| Jun-30-15 | Reiterated |
JMP Securities |
Mkt Outperform |
$25 → $33 |
|
| Jun-19-15 | Reiterated |
Leerink Partners |
Outperform |
$26 → $38 |
|
| Aug-07-14 | Initiated |
Noble Financial |
Buy |
$18 |
|
|
|
| Apr-05-20 09:57AM | Despite Lacking Profits Heron Therapeutics (NASDAQ:HRTX) Seems To Be On Top Of Its Debt Simply Wall St. |
| Mar-02-20 09:05AM | Heron Therapeutics (HRTX) Reports Q4 Loss, Tops Revenue Estimates Zacks |
| 07:30AM | Heron Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2019 and Highlights Recent Corporate Updates PR Newswire |
| Feb-27-20 01:19PM | Analysts: 3 Beaten-Down Stocks to Buy on Weakness TipRanks |
| 08:42AM | The Zacks Analyst Blog Highlights: Moderna, Incyte, Heron Therapeutics and NGM Biopharmaceuticals Zacks |
| Feb-26-20 04:42PM | Biotech Stock Roundup: MRNA Surges, Pipeline Updates from INCY, HRTX & NGM Bio Zacks |
| Feb-21-20 12:30PM | Heron Therapeutics (HRTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release Zacks |
| Feb-20-20 07:06AM | The Daily Biotech Pulse: Heron Pain Drug Review Extended, Disappointment For Teva In Tourette Syndrome Study Benzinga |
| Feb-19-20 06:16PM | 3 Strong Buy Healthcare Stocks With Fast-Approaching Catalysts TipRanks |
| Feb-18-20 04:05PM | Heron Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference PR Newswire |
| Jan-27-20 11:01AM | Introducing Heron Therapeutics (NASDAQ:HRTX), The Stock That Zoomed 186% In The Last Five Years Simply Wall St. |
| Jan-22-20 08:53AM | Heron Therapeutics (HRTX) Catches Eye: Stock Jumps 6.8% Zacks +6.61% |
| Jan-13-20 08:30AM | Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises PR Newswire +5.66% |
| Dec-21-19 08:27AM | When Will Heron Therapeutics, Inc. (NASDAQ:HRTX) Turn A Profit? Simply Wall St. |
| Dec-16-19 04:05PM | Heron Therapeutics Announces Publication of the Mechanism of Action Data for HTX-011, a Dual-Acting Local Anesthetic Being Developed for Management of Postoperative Pain PR Newswire |
| Dec-12-19 01:44PM | Hedge Funds Cashed Out Of Heron Therapeutics Inc (HRTX) Too Early Insider Monkey |
| Dec-10-19 05:18AM | Moving Average Crossover Alert: Heron Therapeutics Zacks |
| Dec-06-19 08:00AM | 12 Biotech Stocks Primed For A Short Squeeze Benzinga |
| Dec-03-19 07:30AM | Health Canada Grants Priority Review Status for Heron Therapeutics' New Drug Submission for HTX-011 for Management of Postoperative Pain PR Newswire |
| Nov-26-19 04:05PM | Heron Therapeutics to Present at the Evercore ISI HealthCONx Conference PR Newswire |
| Nov-25-19 09:13AM | Heron Therapeutics, Inc. (HRTX) Shares March Higher, Can It Continue? Zacks |
| Nov-22-19 03:22PM | 3 Strong Buy Biotech Stocks to Watch After Stifel Healthcare Conference TipRanks |
| Nov-15-19 09:00AM | Heron Therapeutics (HRTX) Upgraded to Buy: Here's Why Zacks |
| 08:24AM | Heron Therapeutics, Inc. Third-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For Next Year Simply Wall St. |
| Nov-14-19 04:05PM | Heron Therapeutics to Present at the Jefferies London Healthcare Conference PR Newswire |
| Nov-13-19 04:05PM | Heron Therapeutics to Present at the Stifel 2019 Healthcare Conference PR Newswire |
| Nov-12-19 09:45AM | Heron Therapeutics (HRTX) Reports Q3 Loss, Tops Revenue Estimates Zacks |
| 08:30AM | Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2019 and Highlights Recent Corporate Updates PR Newswire |
| Nov-11-19 01:59PM | Is Heron Therapeutics, Inc.'s (NASDAQ:HRTX) CEO Pay Fair? Simply Wall St. |
| Oct-30-19 10:33AM | Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: Should You Buy? Zacks |
| 05:15AM | 2 Small Biotech Stocks Spurt Ahead on Positive Developments TheStreet.com |
| Oct-28-19 09:08AM | Is Heron Therapeutics Inc (HRTX) Going to Burn These Hedge Funds? Insider Monkey +5.86% |
| 08:30AM | Heron Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for HTX-011 for Management of Postoperative Pain PR Newswire |
| Oct-22-19 08:30AM | Heron Announces FDA Approval of Supplemental New Drug Application to Expand CINVANTI® Label for Single-Dose Regimen for Patients Receiving Moderately Emetogenic Chemotherapy (MEC) PR Newswire |
| Oct-07-19 12:14PM | Weekly CEO Buys Highlight GuruFocus.com |
| Oct-04-19 10:00PM | Bragar Eagel & Squire is Investigating Certain Officers and Directors of Healthcare Services Group, Heron Therapeutics, Immunomedics, and Karyopharm and Encourages Investors to Contact the Firm GlobeNewswire -10.04% |
| 06:10AM | How Heron Therapeutics, Inc. (NASDAQ:HRTX) Can Impact Your Portfolio Volatility Simply Wall St. |
| Oct-03-19 10:37PM | Heron Therapeutics Announces Pricing of Public Offering of Common Stock PR Newswire |
| 04:01PM | Heron Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire |
| 09:42AM | Heron Therapeutics (HRTX) Catches Eye: Stock Jumps 6.2% Zacks |
| Oct-02-19 12:23PM | Heron Shares Rise on Phase III Results of Agent Used in Knee Replacements TheStreet.com +6.15% |
| 07:45AM | Heron Announces Positive Topline Results from Phase 3b Clinical Study of HTX-011 in Total Knee Arthroplasty PR Newswire |
| Oct-01-19 04:10PM | Heron Therapeutics Appoints Kimberly Manhard to Board of Directors PR Newswire -5.08% |
| 04:05PM | Heron Therapeutics Appoints Stephen Davis to Board of Directors PR Newswire |
| 08:30AM | Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Management of Postoperative Pain PR Newswire |
| Sep-25-19 04:05PM | Heron Therapeutics to Present at the 2019 Cantor Global Healthcare Conference PR Newswire |
| Sep-04-19 10:00AM | How Many Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Did Insiders Buy, In The Last Year? Simply Wall St. |
| Aug-30-19 06:14PM | 5 Health Care Stocks in Gurus' Portfolios GuruFocus.com |
| Aug-29-19 07:31AM | The Smartest People on Wall Street Are Buying These 3 Stocks -- Should You? Motley Fool +6.47% |
| Aug-20-19 08:30AM | Heron Therapeutics Announces Publication of Results from EPOCH 2, a Phase 3 Study of HTX-011 in Patients Undergoing Hernia Repair Surgery PR Newswire |
| Aug-06-19 03:40PM | Biotech Stocks to Watch Through the 2nd Half of 2019 GuruFocus.com |
| Aug-05-19 03:30PM | FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of HRTX, EGBN and CARB ACCESSWIRE |
| 03:00PM | Final Deadline:(HRTX) Heron Therapeutics, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Plaintiff Deadline: August 5, 2019 PR Newswire |
| 02:18PM | Is Heron Therapeutics (NASDAQ:HRTX) Using Debt Sensibly? Simply Wall St. |
| 10:45AM | SHAREHOLDER ALERT: HRTX RBGLY JE: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE |
| 10:30AM | Final Deadline:(HRTX) Heron Therapeutics, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Plaintiff Deadline: August 5, 2019 ACCESSWIRE |
| 09:45AM | Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates Zacks |
| 08:30AM | Heron Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2019 and Highlights Recent Corporate Updates PR Newswire |
| 08:15AM | MONDAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire |
| Aug-02-19 03:30PM | CLASS ACTION UPDATE for HRTX, EROS and MNK: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE |
| 03:00PM | Final Deadline: (HRTX) Heron Therapeutics, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Plaintiff Deadline: August 5, 2019 GlobeNewswire |
| 09:43AM | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of HRTX, STG, PVTL and GTT GlobeNewswire |
| 07:10AM | Pawar Law Group Reminds Investors of August 5 Deadline in Securities Class Action Lawsuit Against Heron Therapeutics, Inc. HRTX GlobeNewswire |
| Aug-01-19 04:00PM | The Gross Law Firm Announces Class Actions on Behalf of Shareholders of HRTX, RLGY and NFLX ACCESSWIRE |
| 02:46PM | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Heron Therapeutics, Inc. To Contact The Firm GlobeNewswire |
| Jul-31-19 02:00PM | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of HRTX, PVTL and INS ACCESSWIRE |
| 12:53PM | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Heron Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline HRTX GlobeNewswire |
| 11:15AM | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of HRTX, PVTL and RBGLY ACCESSWIRE |
| 10:29AM | Approaching Deadline: (HRTX) Heron Therapeutics, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Plaintiff Deadline: August 5, 2019 ACCESSWIRE |
| Jul-30-19 07:05PM | The Gross Law Firm Announces Class Actions on Behalf of Shareholders of HRTX, NFLX and LB ACCESSWIRE |
| 06:30PM | Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Heron Therapeutics, Box, Beazer Homes, and Cloudera and Encourages Investors to Contact the Firm GlobeNewswire |
| 11:20AM | CLASS ACTION UPDATE for MMM, HRTX, CTST and NGHC: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire |
| 10:47AM | HRTX CLASS ACTION DEADLINE: Bernstein Liebhard LLP Reminds Investors That Approximately 6 Days Remain To Make A Motion For Lead Plaintiff In A Securities Class Action Lawsuit Against Heron Therapeutics, INC. HRTX GlobeNewswire |
| Jul-29-19 03:00PM | 3 Top Biotech Stocks to Buy Right Now Motley Fool |
| 02:15PM | CLASS ACTION UPDATE for HRTX, STG and RLGY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE |
| 01:32PM | ROSEN, A TOP RANKED LAW FIRM, Reminds Heron Therapeutics, Inc. Investors of Important August 5th Deadline in the Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm HRTX GlobeNewswire |
| 10:45AM | CLASS ACTION UPDATE for CYH, HRTX and EROS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE |
| 10:28AM | Upcoming Deadline: (HRTX) Heron Therapeutics, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action and Lead Plaintiff Deadline: August 5, 2019 ACCESSWIRE |
| 09:10AM | 7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire |
| Jul-26-19 04:15PM | SHAREHOLDER ALERT: HRTX EQT FRED: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE |
| 03:00PM | Heron Therapeutics, Inc. (HRTX), Beazer Homes USA, Inc. (BZH) & Ascena Retail Group, Inc. (ASNA) - Bronstein, Gewirtz & Grossman, LLC Class Action Update GlobeNewswire |
| 01:20PM | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of HRTX, ASNA and FRED ACCESSWIRE |
| 11:00AM | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Heron Therapeutics, Inc. To Contact The Firm ACCESSWIRE |
| 09:54AM | CLASS ACTION UPDATE for HRTX, FDX and EQT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE |
| 09:21AM | Zhang Investor Law Reminds Investors of August 5 Deadline in Securities Class Action Lawsuit Against Heron Therapeutics, Inc. HRTX GlobeNewswire |
| Jul-25-19 10:45AM | The Gross Law Firm Announces Class Actions on Behalf of Shareholders of HRTX, DBD and RLGY ACCESSWIRE |
| 10:21AM | HRTX CLASS ACTION DEADLINE: Bernstein Liebhard LLP Reminds Investors That Approximately 11 Days Remain to Make a Motion for Lead Plaintiff in a Securities Class Action Lawsuit Against Heron Therapeutics, Inc. HRTX GlobeNewswire |
| Jul-24-19 11:00AM | SHAREHOLDER ALERT: HRTX PVTL OMCL: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines ACCESSWIRE |
| 10:01AM | Heron Therapeutics, Inc. (HRTX), Beazer Homes USA, Inc. (BZH) & Ascena Retail Group, Inc. (ASNA) - Bronstein, Gewirtz & Grossman, LLC Class Action Update ACCESSWIRE |
| Jul-23-19 09:50PM | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CYH, HRTX and PVTL ACCESSWIRE |
| 09:30PM | Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against A.O. Smith Corporation, Community Health Systems, Metro Bank, and Heron Therapeutics and Encourages Investors to Contact the Firm GlobeNewswire |
| 06:21PM | Federman & Sherwood Reminds Investors of Imminent Lead Plaintiff Deadline in Securities Class Action Lawsuit Against Heron Therapeutics, Inc. Business Wire |
| 05:35PM | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of HRTX, PVTL and FRED ACCESSWIRE |
| 05:00PM | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Heron Therapeutics, Inc. To Contact The Firm GlobeNewswire |
| Jul-22-19 07:05PM | The Gross Law Firm Announces Class Actions on Behalf of Shareholders of MBNKF, HRTX and CLDR ACCESSWIRE |
| 05:16PM | Pawar Law Group Reminds Investors of August 5 Deadline in Securities Class Action Lawsuit Against Heron Therapeutics, Inc. HRTX GlobeNewswire |
| 04:10PM | FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of HRTX, CLDR and PYX ACCESSWIRE |
| 02:15PM | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Heron Therapeutics, Inc. To Contact The Firm ACCESSWIRE |
| 11:00AM | CLASS ACTION UPDATE for LTHM, HRTX and BOX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders ACCESSWIRE |
| 10:10AM | UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Heron Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire |
|
|
|
|
| Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. The company is also developing CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy; and HTX-011, an investigational, long-acting, and extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for post-operative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| MANHARD KIMBERLY | Executive VP, Drug Development | Nov 29 | Option Exercise | 13.00 | 24,000 | 312,000 | 24,000 | Dec 03 06:30 PM | | MANHARD KIMBERLY | Executive VP, Drug Development | Nov 29 | Sale | 26.00 | 24,000 | 624,000 | 0 | Dec 03 06:30 PM | | TANG KEVIN C | Director | Oct 04 | Buy | 17.50 | 285,714 | 4,999,995 | 5,799,810 | Oct 07 05:18 PM | | Quart Barry D | Chief Executive Officer | Oct 03 | Buy | 17.50 | 4,571 | 79,993 | 94,652 | Oct 04 07:58 PM | | POYHONEN JOHN | EVP, Chief Commercial Officer | Oct 03 | Buy | 17.50 | 5,143 | 90,003 | 18,143 | Oct 04 07:56 PM | | POYHONEN JOHN | Director | May 22 | Buy | 17.55 | 3,000 | 52,650 | 13,000 | May 23 08:39 AM | | Christian Waage | Director | May 15 | Buy | 18.04 | 1,400 | 25,262 | 1,400 | May 16 08:44 AM | | MANHARD KIMBERLY | Executive VP, Drug Development | May 01 | Sale | 18.86 | 1,109 | 20,918 | 0 | May 02 08:40 PM |
|
|
|
|
|
|
